[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Ohyama et al., 2020 - Google Patents

Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins

Ohyama et al., 2020

View HTML
Document ID
8848405875638798382
Author
Ohyama Y
Nakajima K
Renfrow M
Novak J
Takahashi K
Publication year
Publication venue
Expert review of proteomics

External Links

Snippet

Introduction Protein glycosylation influences characteristics such as folding, stability, protein interactions, and solubility. Therefore, glycan moieties of therapeutic proteins and proteins that are likely associated with disease pathogenesis should be analyzed in-depth, including …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/746—Erythropoetin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins

Similar Documents

Publication Publication Date Title
Trbojević-Akmačić et al. High-throughput glycomic methods
Lingg et al. The sweet tooth of biopharmaceuticals: importance of recombinant protein glycosylation analysis
Duivelshof et al. Therapeutic Fc‐fusion proteins: current analytical strategies
Zhang et al. Glycan analysis of therapeutic glycoproteins
Beyer et al. Microheterogeneity of recombinant antibodies: analytics and functional impact
Jansen et al. LaCyTools: a targeted liquid chromatography–mass spectrometry data processing package for relative quantitation of glycopeptides
Hong et al. A method for comprehensive glycosite-mapping and direct quantitation of serum glycoproteins
O’Flaherty et al. The sweet spot for biologics: recent advances in characterization of biotherapeutic glycoproteins
Chandler et al. Multi-isotype Glycoproteomic characterization of serum antibody heavy chains reveals isotype-and subclass-specific N-glycosylation profiles*[S]
Sjögren et al. On enzymatic remodeling of IgG glycosylation; unique tools with broad applications
Ohyama et al. Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins
Liu et al. IgG N-glycans
Trbojević-Akmačić et al. High-throughput analysis of immunoglobulin G glycosylation
Shrivastava et al. N-Glycosylation of monoclonal antibody therapeutics: A comprehensive review on significance and characterization
Zaytseva et al. Heritability of human plasma N-glycome
Wang et al. Simultaneous release and labeling of O-and N-glycans allowing for rapid glycomic analysis by online LC-UV-ESI-MS/MS
M Wooding et al. Characterization of pharmaceutical IgG and biosimilars using miniaturized platforms and LC-MS/MS
Hansen et al. Immunoglobulin A glycosylation and its role in disease
Wagner et al. Post-HDX deglycosylation of Fc gamma receptor IIIa glycoprotein enables HDX characterization of its binding interface with IgG
Liu et al. Challenges and strategies for a thorough characterization of antibody acidic charge variants
Hammura et al. Synthetic glycopeptides allow for the quantitation of scarce nonfucosylated IgG Fc N-glycans of therapeutic antibody
US12084686B2 (en) Antibodies with modulated glycan profiles
Argentova et al. Features, modulation and analysis of glycosylation patterns of therapeutic recombinant immunoglobulin A
Guan et al. An Integrated Strategy Reveals Complex Glycosylation of Erythropoietin Using Mass Spectrometry
Sanda et al. LC-MS/MS-PRM Quantification of IgG glycoforms using stable isotope labeled IgG1 Fc glycopeptide standard